CCND1 Amplification Predicts Sensitivity to Chemotherapy and Chemoradiotherapy in Head and Neck Squamous Cell Carcinoma

Ryuichiro Ishiguro, Masato Fujii, Taku Yamashita, Masatsugu Tashiro, Toshiki Tomita, Kaoru Ogawa, Kaori Kameyama

Research output: Contribution to journalArticle

12 Citations (Scopus)


Background: Cyclin D1 has been reported to be associated with poor prognosis in head and neck squamous cell carcinoma (HNSCC). Patients and Methods: FISH was performed on 58 patients. Thirty-two received neoadjuvant chemotherapy (NAC) as primary treatment and 21 with hypopharyngeal squamous cell carcinoma (HPC) received chemoradiotherapy. Results: CCND1 amplification was identified in 31 (53%) patients and the incidence was higher in HPC (p=0.0068). Four (31%) out of 13 patients with CCND1 amplification responded to NAC whereas the response rate in the non-amplified group was 79% (p=0.011). CCND1 amplification with a homogeneously staining region (HSR) was accompanied by cyclin D1 protein overexpression (p<0.0001). HPC showed HSR more frequently (p=0.033) and the survival rate of the subgroup with HSR was lower than that without (p<0.05). Conclusion: Detection of CCND1 amplification using FISH may be a useful marker of sensitivity to NAC and chemoradiotherapy for HNSCC.

Original languageEnglish
Pages (from-to)5213-5220
Number of pages8
JournalAnticancer research
Issue number6 D
Publication statusPublished - 2003 Nov 1



  • Chemoradiotherapy
  • Cyclin D1
  • Fluorescence in situ hybridization (FISH)
  • Head and neck squamous cell carcinoma (HNSCC)
  • Homogeneously staining region (HSR)
  • Immunohistochemistry
  • Neoadjuvant chemotherapy (NAC)

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this